Ribociclib Succinate

Ribociclib Succinate is a selective CDK4/6 inhibitor approved for use with other drugs to treat hormone receptor-positive, HER2-negative breast cancer . Ribociclib Succinate is used with an aromatase inhibitor in women with stage II or stage III early breast cancer at high risk of recurrence, and with fulvestrant in women whose cancer has spread . Ribociclib Succinate is also available in a combination pack with letrozole . Ribociclib Succinate is supplied as a crystalline solid and is available as both an API for pharmaceutical manufacturing and as an analytical reference standard. Multiple crystalline forms of Ribociclib Succinate have been identified and patented, including forms SRS-I, SRS-II, and various Cipla and Mylan forms .

Product Parameters

Why Cosperpharm?

When your oncology API manufacturing campaign or ANDA filing requires reliable ribociclib succinate and reference standards, Cosperpharm delivers Ribociclib Succinate with the analytical rigor, documentation depth, and supply flexibility that pharmaceutical customers demand.

Crystalline form control is critical. Ribociclib Succinate exists in multiple crystalline forms (SRS-I, SRS-II, and various patented forms), and polymorph selection can affect dissolution, bioavailability, and stability . Our analytical release protocol for Ribociclib Succinate includes HPLC purity verification, X-ray powder diffraction (XRPD) for form identification, identity confirmation via NMR and MS, and residual solvent analysis—because your formulation's performance depends on consistent crystalline form.

Documentation that supports regulatory submission. As a key API for HR+/HER2- breast cancer treatment, every shipment of Ribociclib Succinate includes a Certificate of Analysis (COA) with batch-specific HPLC purity, XRPD pattern, and residual solvent data. DMF-ready documentation, stability summaries, and custom quality agreements are available upon request.

Flexible supply across all development stages. Cosperpharm supplies Ribociclib Succinate from reference standard quantities for QC impurity profiling, to pilot-scale batches for process validation, to commercial-scale quantities for pharmaceutical manufacturing.

Technical support for crystalline form development. Our process chemistry team can advise on polymorph screening, form control strategies, and analytical methods for detecting form conversion.

FAQ

Q1: What is Ribociclib Succinate used for?

A: Ribociclib Succinate is used with aromatase inhibitors or fulvestrant for hormone receptor-positive, HER2-negative breast cancer .

Q2: What is the mechanism of action?

A: Ribociclib Succinate selectively inhibits CDK4 and CDK6, blocking cell cycle progression.

Product Quality Assurance

Each batch of Ribociclib Succinate undergoes HPLC purity verification, XRPD form identification, identity confirmation via NMR and MS, water content determination, and residual solvent analysis. Full batch traceability and COA documentation are provided.

Contact Us

Need Ribociclib Succinate for your oncology API manufacturing or analytical program? Contact Cosperpharm for pricing, documentation, or technical support.